CoChat
Sign Up
Cited by 25Cannabis and Cannabinoid ResearchHealth, Medicine and SocietyBiomedical Ethics and Regulation

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

The medical cannabis regulatory framework in Canada: A narrative review

Ng, Jeremy Y., Homayouni, Pargol, Usman, Sana, Gomes, Zoya·2022·European Journal of Integrative Medicine
DOI 10.1016/j.eujim.2022.102104
Open this paper in CoChat — free account

Overview

Integrity signals

Registry

Crossref · 10.1016/j.eujim.2022.102104

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The scope of the review was limited to recreational legalization and did not consider other forms of policy changes such as medicinal legalization or decriminalization.

    “Additionally, the scope of the review was limited to recreational legalization and did not consider other forms of policy changes such as medicinal legalization or decriminalization, as these have been summarized more comprehensively in prior reviews.112-114”

    From The Impact of Recreational Cannabis Legalization on Cannabis Use and Associated Outcomes: A Systematic Review (2023) · cites this paper as [112]

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 41

  1. Ludanyi, 2008, Downregulation of the CB1 Cannabinoid Receptor and related molecular elements of the endocannabinoid system in epileptic human hippocampus, J. Neurosci., 28, 2976, 10.1523/JNEUROSCI.4465-07.2008 · DOI
  2. Abrams, 2015, Cannabis in cancer care, Clin. Pharmacol. Ther., 97, 575, 10.1002/cpt.108 · DOI
  3. Allan, 2018, Systematic review of systematic reviews for medical cannabinoids–Pain, nausea and vomiting, spasticity, and harms, Can. Fam. Physician Med. Fam. Can., 64, e78
  4. Lee, 2018, Medical cannabis for neuropathic pain, Curr. Pain Headache Rep., 22, 8, 10.1007/s11916-018-0658-8 · DOI
  5. Walsh, 2013, Cannabis for therapeutic purposes–Patient characteristics, access, and reasons for use, Int. J. Drug Policy, 24, 511, 10.1016/j.drugpo.2013.08.010 · DOI
  6. Ziemianski, 2015, Canada's Marihuana for Medical Purposes Regulations–A synopsis for health professionals, J. Hosp. Adm., 4, 79
  7. Belle-Isle, 2007, Barriers to access to medical cannabis for Canadians living with HIV/AIDS, AIDS Care, 19, 500, 10.1080/09540120701207833 · DOI
  8. Belle-Isle, 2014, Barriers to access for Canadians who use cannabis for therapeutic purposes, Int. J. Drug Policy, 25, 691, 10.1016/j.drugpo.2014.02.009 · DOI
  9. Lucas, 2008, Regulating compassion–An overview of Canada's federal medical cannabis policy and practice, Harm Reduct. J., 5, 5, 10.1186/1477-7517-5-5 · DOI
  10. Valleriani, 2020, Identity narratives in the face of market competition–The emerging legal medical cannabis market in Canada, Drugs Educ. Prev. Policy, 27, 37, 10.1080/09687637.2018.1531828 · DOI
  11. Ries NM. Prescribe with Caution–The Response of Canada's Medical Regulatory Authorities to the Therapeutic Use of Cannabis. 2016;9(2):40.
  12. Ko, 2016, Medical cannabis–The Canadian perspective, J. Pain Res., 9, 735, 10.2147/JPR.S98182 · DOI
  13. Stambrook, 2012, Cost-benefit analysis of regulatory changes for access to Marihuana for medical purposes, Final Rep., 183
  14. Johnson, 2011, Consequences of large-scale production of Marijuana in residential buildings, Indoor Built Environ., 21, 595, 10.1177/1420326X11411954 · DOI
  15. Martyny, 2013, Potential exposures associate with indoor Marijuana growing operations, J. Occup. Environ. Hyg., 10, 622, 10.1080/15459624.2013.831986 · DOI
  16. La Barge, 2005, Indoor Marijuana growing operations, Police Chief, 72, 28
  17. Bean, 2016, Medical cannabis–Identifying ethical and policy implications for healthcare organizations in Canada, J. Pain Manag., 9, 473
  18. Bean, 2015, A vaping matter–E-cigarette use in health care organizations, Hastings Cent. Rep., 45, 11, 10.1002/hast.512 · DOI
  19. Capler, 2017, Are dispensaries indispensable? Patient experiences of access to cannabis from medical cannabis dispensaries in Canada, Int. J. Drug Policy, 47, 1, 10.1016/j.drugpo.2017.05.046 · DOI
  20. Garis L, Clare J, Maxim P, Illuminating the Hazards of Residential Marijunia Grow Operations. http://rgdoi.net/10.13140/RG.2.1.2846.5129, 2015 (accessed 5 May 2020). · DOI
  21. Clare, 2017, Medicinal marijuana production creates problem residential properties–A routine activity theory explanation and a situational crime-prevention solution, Can. J. Criminol. Crim. Justice, 59, 143
  22. Balneaves, 2019, Guarding their practice”–A descriptive study of Canadian nursing policies and education related to medical cannabis, BMC Nurs., 18, 66, 10.1186/s12912-019-0390-7 · DOI
  23. Bahji, 2019, International perspectives on the implications of cannabis legalization–A systematic review & thematic analysis, Int. J. Environ. Res. Public Health, 16, 3095, 10.3390/ijerph16173095 · DOI
  24. Fischer, 2020, Initial indicators of the public health impacts of non-medical cannabis legalization in Canada, EClinicalMedicine, 20, 10.1016/j.eclinm.2020.100294 · DOI
  25. Kahan, 2019, Cannabis industry and medical cannabis clinics need regulation, Can. Fam. Physician Med. Fam. Can., 65, 864
  26. Matielo, 2018, A bibliometric analysis of Cannabis publications–Six decades of research and a gap on studies with the plant, Publications, 6, 40, 10.3390/publications6040040 · DOI
  27. Liu, 2020, Global trends in cannabis and cannabidiol research from the year 1940 to 2019, Curr. Pharm. Biotechnol.
  28. Ruheel, 2021, Facilitators and barriers to the regulation of medical cannabis–A scoping review of the peer-reviewed literature, Harm Reduct. J., 18, 106, 10.1186/s12954-021-00547-8 · DOI
  29. Cairns, 2017, Why support a separate medical access framework for cannabis?, Can. Med. Assoc. J., 189, E927, 10.1503/cmaj.170427 · DOI
  30. Webster, 2018, Urgent need for federal investment in research on cannabis health impacts, say researchers, Can. Med. Assoc. J., 190, E149, 10.1503/cmaj.109-5554 · DOI
  31. Lake, 2015, Prescribing medical cannabis in Canada–Are we being too cautious?, Can. J. Public Health, 106, e328, 10.17269/cjph.106.4926 · DOI
  32. Cohen, 2010, Medical Marijuana 2010–It's time to fix the regulatory vacuum, J. Law Med. Ethics, 38, 654, 10.1111/j.1748-720X.2010.00519.x · DOI
  33. Ng, 2021, Attitudes toward medical cannabis among family physicians practising in Ontario, Canada–A qualitative research study, CMAJ Open, 9, E342, 10.9778/cmajo.20200187 · DOI
  34. Zolotov, 2021, Medical cannabis education among healthcare trainees–A scoping review, Complement. Ther. Med., 58, 10.1016/j.ctim.2021.102675 · DOI
  35. Prosk, 2021, The model of care at a leading medical cannabis clinic in Canada, Complement. Ther. Med., 60, 10.1016/j.ctim.2021.102740 · DOI
  36. Pierre, 2020, Cannabis education needs assessment among Canadian physicians-in-training, Complement. Ther. Med., 49, 10.1016/j.ctim.2020.102328 · DOI
  37. Hawley, 2020, The impact of legalization of access to recreational Cannabis on Canadian medical users with Cancer, BMC Health Serv. Res., 20, 977, 10.1186/s12913-020-05756-8 · DOI
  38. Shover, 2019, Six policy lessons relevant to cannabis legalization, Am. J. Drug Alcohol Abuse, 45, 698, 10.1080/00952990.2019.1569669 · DOI
  39. Pacula, 2002, State medical marijuana laws–Understanding the laws and their limitations, J. Public Health Policy, 23, 413, 10.2307/3343240 · DOI
  40. Owens, 2018, CMA position against separate regulations for medical cannabis draws ire and insults, Can. Med. Assoc. J., 190, E574, 10.1503/cmaj.109-5594 · DOI
  41. 2016, Standing senate committee on social affairs, Sci. Technol.

Cited by

Sorted by citations

Metadata

Authors
Ng, J. Y., Homayouni, P., Usman, S., & Gomes, Z.
Affiliations
McMaster University (CA)
Corresponding author
Ng, Jeremy Y.
ORCID
Venue
European Journal of Integrative Medicine
Publisher
Elsevier BV
Published
2022-02
Volume
50
Pages
102104
ISSN
1876-3820 (ISSN-L)
DOI
10.1016/j.eujim.2022.102104
OpenAlex
W4213255345
Cited by
25
References
2
Citations by year
2026: 1 · 2025: 8 · 2024: 5 · 2023: 8 · 2022: 3
FWCI
0.86
Type
journal article
Language
en
Open access
closed
Licence
Locations
European Journal of Integrative Medicine (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
  • Health Sciences › Health Professions › General Health Professions › Health, Medicine and Society
  • Health Sciences › Nursing › Issues, ethics and legal aspects › Biomedical Ethics and Regulation
Keywords
medical cannabis, cannabis regulation, Cannabis Act, patient access, regulatory compliance, Canada

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review